Finerenone Cuts Albuminuria 42% in Glomerular Disease, Slowing eGFR Decline
Updated
Updated · Medical Dialogues · Jun 25
Finerenone Cuts Albuminuria 42% in Glomerular Disease, Slowing eGFR Decline
3 articles · Updated · Medical Dialogues · Jun 25
Summary
Up to 32 months of FIND-CKD follow-up showed finerenone slowed kidney-function loss in chronic kidney disease tied to glomerular diseases, trimming annual eGFR decline by 0.73 mL/min/1.73 m² versus placebo.
The total eGFR slope was -3.50 mL/min/1.73 m² per year with finerenone versus -4.23 with placebo, indicating a slower deterioration in renal function.
At 12 months, finerenone reduced albuminuria by 42% and lowered the risk of kidney failure or sustained eGFR decline of at least 40% by 26%, with a hazard ratio of 0.74.
Event rates were 7.42 versus 9.60 per 100 patient-years, and the exploratory analysis said the kidney-protective effect was generally consistent across glomerular disease subtypes.
The findings extend finerenone's reported renal benefits beyond diabetic CKD, after a separate June 25 study linked the drug to lower cardiovascular, kidney and CKM event risk in type 2 diabetes.
New guidelines link heart, kidney, and metabolic diseases. Is one pill the key to treating them as a single, interconnected syndrome?
This breakthrough drug helps reverse a syndrome affecting most adults. But who might be left behind by its high cost?
Finerenone’s 2026 Breakthroughs: Improved Outcomes in CKD and HFpEF Backed by FINEARTS-HF and Subgroup Analyses
Overview
As of mid-2026, finerenone is becoming a key therapy for cardiorenal-metabolic (CKM) conditions, with new research expanding its benefits beyond chronic kidney disease into heart failure populations. The pivotal FINEARTS-HF trial showed that finerenone can reduce cardiovascular events in patients with heart failure and preserved or mildly reduced ejection fraction. Detailed subgroup analyses from this trial provide a deeper understanding of how different patient groups respond to treatment. These breakthroughs highlight finerenone’s growing role in protecting a wider range of patients and shaping future treatment strategies for CKM conditions.